Category - Developments

Developments

Ortho RTi in pact with CMO to manufacture cGMP quantities of Ortho-R

Ortho Regenerative Technologies (CSE:ORTH) entered into an agreement with a leading contract manufacturing organization operating within the global biopharmaceutical industry to begin work on providing Ortho RTi with...

September 6, 2018

Developments

Titan, Nevada Center for Behavioral Health collaborate on Probuphine treatment of OUD in criminal justice system

Titan Pharmaceuticals (NASDAQ:TTNP) launched a pilot program in collaboration with the Nevada Center for Behavioral Health to evaluate a medication-assisted treatment program utilizing Titan’s Probuphine (buprenorphine)...

September 4, 2018

Developments

Urovant Sciences licenses gene therapy for overactive bladder

Closely-held Urovant Sciences licensed from Ion Channel Innovations global rights for an investigational gene therapy, hMaxi-K, for patients with overactive bladder (OAB) symptoms, who have failed oral pharmacologic...

August 28, 2018

Developments

Esperion posts positive Phase 3 bempedoic acid/ezetimibe combo results

Esperion (NASDAQ:ESPR) reported positive top-line results from a Phase 3 study of its bempedoic acid/ezetimibe combination pill for the treatment of LDL-C lowering. The study included 382 high-risk patients taking...

August 28, 2018

Developments

Sierra Oncology acquires momelotinib from Gilead

Sierra Oncology (NASDAQ:SRRA) has acquired the drug candidate, momelotinib, from Gilead Sciences (NASDAQ:GILD) for a $3-million upfront fee and potential milestone payments of up to $195-million, which are largely...

August 22, 2018

Developments

FDA accepts Evoke Pharma NDA for Gimoti; PDUFA date April 1

The FDA has accepted for review Evoke Pharma’s (NASDAQ:EVOK) 505(b)(2) NDA for Gimoti, the company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic...

August 16, 2018

Developments

electroCore in research pact with Mass General

electroCore (NASDAQ:ECOR) is collaborating with Massachusetts General Hospital (MGH) in a neuroinflammation research program. Under the program, electroCore’s non-invasive vagus nerve stimulation (nVNS) will be studied...

August 9, 2018

Developments

Growing dysphagia incidence driving development of alternative modes of drug delivery

A new study published in the peer-reviewed journal, Dysphagia, suggests that the proportion of seniors with swallowing problems in the U.S. is expected to top 20% by 2030 from 15% currently. “Dysphagia has...

August 7, 2018

Developments

Titan Pharma, Molteni amend asset, supply, support agreement

Titan Pharmaceuticals (NASDAQ:TTNP) has entered into an amendment of an earlier asset purchase, supply and support agreement with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A., which allowed Molteni...

August 3, 2018

Developments

Vasomune, AnGes in pact to target vascular leakage

Closely-held Vasomune Therapeutics and AnGes (Tokyo, TYO:4563) signed a global co-development agreement for the development and commercialization of therapeutics treating diseases associated with blood vessel...

July 31, 2018

Category - Developments

General

More